A new neoantigen T-cell player has launched with Neogene Therapeutics nabbing a major $110 million series A.
The funding haul, a significant sum for a first round, was led by by EcoR1 Capital, Jeito Capital and Syncona with continued support from strategic seed investors Vida Ventures, TPG and Two River.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,